Últimas noticias sobre Verastem (NASDAQ:VSTM) Bolsa

Verastem

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Verastem Inc

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares increased by 109.6% to $2.18 during Thursday's regular session. The company's market cap stands at $371.9 million. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) stock increased by 61.42% to $0.52. The market value of their outstanding shares is at $3.4 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) stock increased by 37.97% to $0.46. The company's market cap stands at $13.7 million. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) stock rose 36.93% to $1.14. The company's market cap stands at $19.3 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock increased by 27.16% to $6.46. The company's market cap stands at $33.6 million. </li>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) stock increased by 25.11% to $0.46. The market value of their outstanding shares is at $74.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock declined by 33.9% to $5.55 during Thursday's regular session. The market value of their outstanding shares is at $80.5 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock declined by 31.23% to $4.45. The company's market cap stands at $4.5 million. </li>
<li>Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) stock fell 19.67% to $2.67. The market value of their outstanding shares is at $107.6 million. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) shares declined by 18.24% to $1.47. The market value of their outstanding shares is at $272.7 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) stock fell 15.52% to $0.79. The company's market cap stands at $123.2 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares decreased by 14.99% to $0.67. The company's market cap stands at $2.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ATNF

BDRX

CERS

KZIA

MTEM

PIII

QNRX

RENB

SONN

TLPH

TVGN

VSTM

12 Health Care Stocks Moving In Thursday's Intraday Session

WIIM

Verastem shares are trading lower. The company presented updated data on the Avutometinib And Defactinib combo in recurrent low-grade serous ovarian cancer at IGCS 2024.

<ul>
<li>Robust overall response rates observed (31%&nbsp;overall,&nbsp;44%&nbsp;in KRAS mutant,&nbsp;17%&nbsp;in KRAS wild-type) in patients whose cancer had progressed despite prior treatment with chemotherapy and/or MEK inhibitors and/or bevacizumab</li>
<li>Patients on avutometinib and defactinib achieved a median progression free survival of more than one year (12.9 months); 22 months in KRAS mutant population</li>
<li>The Company recently met with the FDA to review the mature data set and remains on track to complete the NDA submission in October 2024</li>
<li>Additional data to be presented at the IGCS meeting and during Company-hosted investor conference call and webcast today, October 17, 2024 at 4:30 pm EDT</li>
</ul>

News

Verastem Oncology Presents Updated Data On Avutometinib And Defactinib Combo In Recurrent Low-Grade Serous Ovarian Cancer At IGCS 2024

Verastem Oncology Announced Further Details For Its Late-breaking Presentation Of Mature Data From The Ongoing Phase 2 Ramp 201 Clinical Trial To Be Presented As An Oral Presentation At A Plenary Session At The International Gynecologic Cancer Society

Verastem shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and announced a $13 price target.

Guggenheim analyst Michael Schmidt initiates coverage on Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy rating and announces Price Target of $13.

Price Target

Initiation

Analyst Ratings

Guggenheim Initiates Coverage On Verastem with Buy Rating, Announces Price Target of $13

Verastem Oncology To Present Late-breaking Abstract Of The Mature Data From The Ongoing Phase 2 RAMP 201 Clinical Trial At IGCS Annual Meeting

Truist Securities analyst Srikripa Devarakonda maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy and lowers the price target from $18 to $15.

Truist Securities Maintains Buy on Verastem, Lowers Price Target to $15

HC Wainwright &amp; Co. analyst Sean Lee maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy and lowers the price target from $17.5 to $7.

HC Wainwright & Co. Maintains Buy on Verastem, Lowers Price Target to $7

RBC Capital analyst Gregory Renza maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Outperform and lowers the price target from $16 to $13.

RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $13

Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.95) by 35.79 percent. This is a 42.45 percent increase over losses of $(1.06) per share from the same period last year. The company reported quarterly sales of $10.00 thousand which missed the analyst consensus estimate of $50.00 thousand by 80.00 percent.

Earnings

Earnings Beats

Earnings Misses

Verastem Q2 Adj $(0.61) Beats $(0.95) Estimate, Sales $10.00K Miss $50.00K Estimate

Expect to report updated data from the ongoing RAMP 205 trial in first-line metastatic pancreatic cancer in Q1 2025
Verastem Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), a biopharmaceutical company committed to advancing new medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to avutometinib, a RAF/MEK clamp, in combination with defactinib, a selective FAK inhibitor, for the treatment of pancreatic cancer.

Biotech

General

Verastem Oncology Receives FDA Orphan Drug Designation For Avutometinib And Defactinib For The Treatment Of Pancreatic Cancer; Expects To Report Updated Data From The Ongoing RAMP 205 Trial In First-Line Metastatic Pancreatic Cancer In Q1 2025

Shares of General Dynamics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) fell sharply during Wednesday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/news/earnings/24/07/39934099/general-dynamics-hits-high-revenue-but-faces-earnings-hiccup-in-q2-details">second-quarter EPS results</a>.
Revenue for the quarter increased 18% year-over-year to $11.976 billion, beating the consensus of $11.438 billion. EPS of $3.26 (up 20.7% YoY) missed the consensus of $3.29, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
General Dynamics shares declined 5.2% to $279.26 on Wednesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>NuZee, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUZE#NASDAQ">NUZE</a>) jumped 192% to $3.01.</li>
<li>Dermata Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) rose 142.4% to $3.0799 after falling over 22% on Tuesday.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) surged 134% to $0.0609.</li>
<li>Bone Biologics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) gained 86% to $2.3300.</li>
<li>Carbon Revolution Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREV#NASDAQ">CREV</a>) gained 74.5% to $10.82.</li>
<li>Pieris Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIRS#NASDAQ">PIRS</a>) jumped 73.4% to $13.77 after the company announced that the company entered into a definitive merger agreement with Palvella Therapeutics.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) gained 50% to $0.60 after licensing partner Pfizer&#8217;s Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec met its primary endpoint.</li>
<li>Alpha Teknova, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) gained 28% to $3.2212.</li>
<li>KORE Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KORE#NASDAQ">KORE</a>) gained 21.8% to $2.84.</li>
<li>NaaS Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) rose 20.5% to $6.87 after reporting unaudited 2024 second quarter and first half financial results.</li>
<li>PROG Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRG#NYSE">PRG</a>) climbed 20.4% to $41.71 after the company reported better-than-expected second-quarter financial results. Also, the company raised its FY24 guidance above estimates.</li>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) gained 19.4% to $94.69. The company on Monday announced a private placement financing.</li>
<li>Silynxcom Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYNX#NYSE">SYNX</a>) rose 18.4% to $3.71. Silynxcom received $815,000 in orders from Israel Defense Forces since July 2024.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares gained 16.4% to $1.0009 after the company announced steady progress in its due diligence efforts in its proposed reverse merger with COVIRIX Medical and anticipates completion by the end of August 2024.</li>
<li>Flex Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLEX#NASDAQ">FLEX</a>) gained 10.9% to $32.96 after the company reported better-than-expected second-quarter financial results.</li>
<li>Manhattan Associates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) climbed 10.5% to $249.78 after the company reported better-than-expected second-quarter financial results.</li>
<li>Group 1 Automotive, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPI#NYSE">GPI</a>) gained 9.6% to $333.95 after the company reported better-than-expected second-quarter adjusted EPS results.</li>
<li>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) rose 9.2% to $113.18 after the company reported second-quarter financial results.</li>
<li>Allarity Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) gained 8.7% to $0.1809. Allarity Therapeutics revealed on Monday it received a "Wells Notice" from the U.S. Securities and Exchange Commission (SEC).</li>
<li>Mattel, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) gained 7.9% to $18.61 after the company reported better-than-expected second-quarter adjusted EPS results.</li>
<li>Seagate Technology Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) shares surged 7.5% to $113.33 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter guidance above estimates.</li>
<li>Alkermes plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) gained 7% to $26.69 after the company reported better-than-expected <a>second-quarter </a>financial results.</li>
<li>Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) gained 6.8% to $148.17 after the company reported better-than-expected second-quarter financial results and the company and raised its FY24 guidance above estimates. Also, the company announced it authorized a $1.5 billion share buyback.</li>
<li>AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) gained 3.1% to $18.78 following second-quarter earnings.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) shares dipped 74.4% to $1.27. Azitra announced the pricing of $10.0 million public offering.</li>
<li>Next Technology Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) fell 58% to $2.42.</li>
<li>Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) dipped 43.8% to $4.25.</li>
<li>Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) fell 37.2% to $2.6199 after the company announced the pricing of a $2 million public offering of 469,340 common shares at $4.24 a share.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) dipped 34.2% to $0.1414.</li>
<li>Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) declined 26.9% to $57.46 after the company reported worse-than-expected quarterly financial results. Also, the company issued its FY25 EPS guidance below estimates.</li>
<li>Conn&#8217;s, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CONN#NASDAQ">CONN</a>) shares fell 26.7% to $0.3717 as the company announced plans to close 71 locations across 13 states.</li>
<li>Vintage Wine Estates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VWE#NASDAQ">VWE</a>) fell 24.5% to $0.0868 after the company announced bankruptcy filing and voluntary delisting and SEC deregistration.</li>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) declined 24.2% to $0.7350 after the company issued an update on Black Lake Uranium Project.</li>
<li>AtlasClear Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATCH#NASDAQ">ATCH</a>) shares declined 23.8% to $0.4228 after gaining 11% on Tuesday.</li>
<li>Verastem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) shares fell 22.7% to $2.7750 after the company reported pricing of $55.0 million public offering of common stock, warrants and pre-funded warrants.</li>
<li>Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) dipped 17.8% to $10.75 after the Phase 2 KINETIC 2 study of SAGE-324 did not demonstrate a statistically significant dose-response relationship on the primary endpoint.</li>
<li>Hawaiian Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HA#NASDAQ">HA</a>) dipped 13% to $11.33.</li>
<li>SFL Corporation Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SFL#NYSE">SFL</a>) shares fell 12.3% to $12.23 after the company announced an offering of 8 million common shares.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares fell 12% to $216.78. Tesla reported weaker-than-expected earnings for its second quarter, while sales topped estimates. The company reported second-quarter deliveries of 443,956 vehicles and production of 410,831 vehicles, down 5% and 14% year-over-year, respectively.</li>
<li>Karooooo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KARO#NASDAQ">KARO</a>) dipped 11.3% to $31.90 as the company announced the launch of secondary public offering of ordinary shares.</li>
<li>Bausch + Lomb Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) fell 10.2% to $15.29.</li>
<li>Kanzhun Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZ#NASDAQ">BZ</a>) dipped 9.5% to $14.41.</li>
<li>Chijet Motor Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJET#NASDAQ">CJET</a>) fell 9.3% to $4.61 after jumping 55% on Tuesday.</li>
<li>Allegro MicroSystems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) dipped 9.1% to $25.14 after the company announced a primary offering of 25 million shares.</li>
<li>Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) shares declined 8.8% to $4.2150 after the company announced the departure of CCO Anil Kapur.</li>
<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) fell 8.4% to $92.45.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) fell 8.2% to $56.97.</li>
<li>Deutsche Bank Aktiengesellschaft (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>) shares fell 8% to $15.69 following second-quarter earnings.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) declined 8% to $14.25.</li>
<li>Weatherford International plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFRD#NASDAQ">WFRD</a>) dipped 7.6% to $123.57 after the company reported worse-than-expected second-quarter financial results.</li>
<li>Roper Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NYSE">ROP</a>) fell 7.4% to $532.08 after the company reported worse-than-expected second-quarter sales results and issued third-quarter adjusted EPS guidance below estimates.</li>
<li>Volato Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) shares fell 7.1% to $0.5479 after gaining around 23% on Tuesday.</li>
<li>Fortive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) fell 6.9% to $71.36 after the company reported worse-than-expected second-quarter sales results and issued FY24 sales guidance below estimates.</li>
<li>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) fell 5.5% to $367.84 after Piper Sandler downgraded the stock from an Overweight to Neutral and lowered its price target from $494 to $404.</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) shares declined 4.1% to $174.29. Alphabet reported upbeat earnings and sales results for its second quarter on Tuesday. The company also announced a cash dividend of 20 cents per share to be paid on Sept.16 to shareholders of record as of Sept. 9.</li>
<li>Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) shares fell 3.8% to $254.72 following third-quarter results.</li>
</ul>
Now Read This:  
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39932485/jim-cramer-calls-axsome-a-double-or-nothing-stock-says-sap-is-incredible">Cramer Calls Axsome A &#8216;Double Or Nothing Stock,&#8217; Says SAP Is &#8216;Incredible</a><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39932485/jim-cramer-calls-axsome-a-double-or-nothing-stock-says-sap-is-incredible">&#8216;</a></li>
</ul>

Intraday Update

Markets

Trading Ideas

ALGM

ALKS

ALLR

ATCH

ATPC

AZTR

BBLG

BLCO

CJET

CONN

CREV

DRMA

ENPH

FLEX

GERN

GOOGL

KARO

KORE

LITM

MANH

NAAS

NIVF

NUWE

NUZE

Next Technology Holding Inc. - Ordinary Shares

NXTT

PIRS

ROKU

SAGE

SGMO

SLNA

SOAR

SYNX

TKNO

TSLA

ULTA

Vintage Wine Estates, Inc. - Common Stock

WFRD

Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Verastem shares are trading lower after the company announced it priced its $55 million public offering of 13,333,334 of its common stocks and accompanying warrants at $3.00 per share and accompanying warrant.

Shares of Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) rose sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/markets/equities/24/07/39916454/whats-going-on-with-enphase-energy-enph-stock">second-quarter financial results</a>.
Enphase Energy reported second-quarter revenue of $303.46 million, missing the consensus estimate of $309.67 million, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. The company reported adjusted earnings of 43 cents per share, missing analyst estimates of 48 cents per share.
Enphase Energy shares gained 6.2% to $110.10 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Dermata Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) rose 146.2% to $3.20 in pre-market trading after falling over 22% on Tuesday.</li>
<li>NuZee, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUZE#NASDAQ">NUZE</a>) gained 87.4% to $1.93 in pre-market trading.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares climbed 65.4% to $24.74 in pre-market trading after jumping 344% on Tuesday.</li>
<li>Allarity Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) gained 41.1% to $0.2350 in pre-market trading. Allarity Therapeutics revealed on Monday it received a "Wells Notice" from the U.S. Securities and Exchange Commission (SEC).</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares gained 30.1% to $1.12 in pre-market trading after the company announced steady progress in its due diligence efforts in its proposed reverse merger with COVIRIX Medical and anticipates completion by the end of August 2024.</li>
<li>Perfect Moment Ltd.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMNT#NASDAQ">PMNT</a>) gained 19% to $2.20 in pre-market trading after gaining around 9% on Tuesday.</li>
<li>ENGlobal Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENG#NASDAQ">ENG</a>) shares gained 15% to $2.00 in pre-market trading.</li>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) shares gained 14.4% to $2.30 in pre-market trading after falling over 17% on Tuesday. 1847 Holdings recently announced a 1-for-13 reverse split.</li>
<li>Seagate Technology Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) shares surged 5.3% to $110.90 in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quarter guidance above estimates.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) shares fell 74.7% to $1.26 in pre-market trading. Azitra announced the pricing of $10.0 million public offering.</li>
<li>Conn&#8217;s, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CONN#NASDAQ">CONN</a>) shares fell 34.9% to $0.33 in pre-market trading as the company announced plans to close 71 locations across 13 states.</li>
<li>Verastem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) shares fell 27.6% to $2.60 in pre-market trading after the company reported pricing of $55.0 million public offering of common stock, warrants and pre-funded warrants.</li>
<li>ATI Physical Therapy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATIP#NYSE">ATIP</a>) shares declined 25.7% to $4.55 in pre-market trading after gaining around 5% on Tuesday.</li>
<li>Volato Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) shares fell 25.2% to $0.4408 in pre-market trading after gaining around 23% on Tuesday.</li>
<li>Chijet Motor Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJET#NASDAQ">CJET</a>) fell 21.1% to $4.01 in pre-market trading after jumping 55% on Tuesday.</li>
<li>AtlasClear Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATCH#NASDAQ">ATCH</a>) shares declined 20.6% to $0.44 in pre-market trading after gaining 11% on Tuesday.</li>
<li>Wheels Up Experience Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UP#NYSE">UP</a>) fell 9.8% to $3.00 in pre-market trading. Wheels Up Experience will release its second quarter financial results on Thursday, Aug. 8.</li>
<li>SFL Corporation Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SFL#NYSE">SFL</a>) shares dipped 9.3% to $12.65 in pre-market trading after the company announced an offering of 8 million common shares.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares fell 7.2% to $228.56 in pre-market trading. Tesla reported weaker-than-expected earnings for its second quarter, while sales topped estimates. The company reported second-quarter deliveries of 443,956 vehicles and production of 410,831 vehicles, down 5% and 14% year-over-year, respectively.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39924118/tesla-at-t-and-3-stocks-to-watch-heading-into-wednesday">Tesla, AT&amp;T And 3 Stocks To Watch Heading Into Wednesday</a></li>
</ul>

Pre-Market Outlook

ATIP

EFSH

PMNT

Why Enphase Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Verastem Oncology, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock and accompanying warrants to purchase up to 13,333,334 shares of its common stock at a combined offering price to the public of $3.00 per share and accompanying warrant. In lieu of common stock to certain investors, Verastem Oncology offered pre-funded warrants to purchase up to an aggregate of 5,000,000 shares of its common stock and accompanying warrants to purchase up to 5,000,000 shares of its common stock at a combined offering price to the public of $2.999 per pre-funded warrant and accompanying warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The warrants have an exercise price of $3.50 per share, are exercisable immediately and will expire 18 months from the date of issuance.

Reported Earlier, Verastem Oncology Prices $55M Public Offering Of 13,333,334 Common Stock, Warrants And Pre-Funded Warrants

Versatem shares are trading lower after the company announced a proposed public offering of common stock, warrants, and pre-funded warrants.

Verastem Oncology, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants to purchase common stock in lieu of common stock for certain investors and accompanying warrants to purchase shares of common stock, in an underwritten public offering. The pre-funded warrants will be issued to certain investors who have elected to purchase them in lieu of shares of common stock in this offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the securities to be sold in the offering are to be sold by Verastem Oncology.
Guggenheim Securities and Cantor are acting as joint book-running managers for the proposed offering.

Offerings

Verastem Oncology Announces Proposed Public Offering Of Common Stock, Warrants And Pre-Funded Warrants; No Size Or Amount Disclosed

Shares of ASP Isotopes Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) fell during Friday's session after the company announced pricing of a $30 million public offering of 12 million <a href="https://www.benzinga.com/quote/ASPI/news">shares at $2.50 per share</a>.
ASP Isotopes shares fell 9.2% to $3.2308 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Vicinity Motor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) shares jumped 133.2% to $0.7910 after the company announced CARB certification for the VMC 1200 class 3 electric truck.</li>
<li>Qualigen Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) shares rose 110% to $0.4335.</li>
<li>TOYO Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOYO#NASDAQ">TOYO</a>) climbed 63.4% to $2.5322.</li>
<li>Nisun International Enterprise Development Group Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NISN#NASDAQ">NISN</a>) jumped 58% to $9.52 following FY23 earnings.</li>
<li>Sentage Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTG#NASDAQ">SNTG</a>) rose 43% to $3.29 after gaining around 5% on Thursday.</li>
<li>Inspire Veterinary Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) gained 40.4% to $7.85.</li>
<li>Crown LNG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) shares jumped 38.8% to $3.3452.</li>
<li>Zapp Electric Vehicles Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) gained 37.6% to $12.66 after the company announced that it entered into a new standby equity purchase agreement with an affiliate of Yorkville Advisors Global to start production and the commercial rollout of the i300 electric urban motorcycle in India.</li>
<li>Instil Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) rose 25.7% to $12.19.</li>
<li>A2Z Smart Technologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZ#NASDAQ">AZ</a>) gained 23.8% to $0.7899.</li>
<li>AgriFORCE Growing Systems Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRI#NASDAQ">AGRI</a>) shares rose 19.3% to $0.0982 after gaining around 7% on Thursday.</li>
<li>S&amp;W Seed Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) gained 18.3% to $0.3375.</li>
<li>Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) gained 17% to $3.9850. The stock may be up on continued strength after the company&#8217;s CEO recently said the co. will need to raise more money to grow, stating Saudi&#8217;s PIF is a &#8216;perfect&#8217; long-term partner on EVs.</li>
<li>China SXT Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) rose 16% to $1.38 after jumping 10% on Thursday.</li>
<li>LL Flooring Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LL#NYSE">LL</a>) surged 16% to $0.8673.</li>
<li>Verastem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) gained 15% to $3.4188. Verastem Oncology said first patient was dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) inhibitor, in a Phase 1/2 trial in China as a part of collaboration with GenFleet Therapeutics.</li>
<li>Immutep Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) shares climbed 14.4% to $2.30 after the company disclosed results for first-line treatment of head and neck squamous cell carcinoma patients with negative PD-L1 expression.</li>
<li>EVgo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) gained 14.2% to $3.8506. Benchmark analyst Michael Legg maintained EVgo with a Buy and raised the price target from $3 to $5.</li>
<li>QuantumScape Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QS#NASDAQ">QS</a>) rose 12.2% to $7.92. QuantumScape recently announced it entered into an agreement with PowerCo to industrialize solid-state batteries.</li>
<li>Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) surged 9.6% to $5.01. Archer Aviation announced it has signed a memorandum of understanding (MOU) with Southwest Airlines Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) to develop operational plans for electric air taxi networks utilizing Archer's eVTOL aircraft at California airports.</li>
<li>Forward Air Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) rose 9.6% to $23.51.</li>
<li>EyePoint Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) gained 8.7% to $10.77.</li>
<li>The Bank of New York Mellon Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) climbed 4.3% to $64.12 following better-than-expected quarterly financial results.</li>
<li>Telefonaktiebolaget LM Ericsson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) rose 3.8% to $6.63 after the company reported better-than-expected second-quarter sales and issued guidance.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Shineco, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SISI#NASDAQ">SISI</a>) shares dipped 53% to $0.9987 after the company announced pricing of a $2 million underwritten public offering.</li>
<li>Kazia Therapeutics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) fell 24.2% to $0.94. HC Wainwright &amp; Co. analyst Sean Lee reiterated Kazia Therapeutics with a Buy and maintained a $2 price target.</li>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) fell 20.5% to $5.83 after surging 85% on Thursday.</li>
<li>Locafy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCFY#NASDAQ">LCFY</a>) dipped 19.3% to $4.92.</li>
<li>Renalytix Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) declined 18.3% to $0.3035. Renalytix recently announced a collaboration with the Steno Diabetes Center, Copenhagen, to advance translation of precision medicine solutions for patients with Diabetes and Chronic Kidney Disease.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) fell 15.5% to $2.04. Pineapple recently engaged Conduit Capital to provide structural internal support, staffing, and assistance with capital-raising activities.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) dipped 14% to $1.43.</li>
<li>MingZhu Logistics Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YGMZ#NASDAQ">YGMZ</a>) declined 13.5% to $1.41.</li>
<li>New Horizon Aircraft Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) shares fell 9.4% to $0.5750 after gaining around 20% on Thursday.</li>
<li>Lipella Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) fell 9.4% to $0.4810 after gaining over 9% on Thursday.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) shares declined 8.5% to $24.00 after gaining around 4% on Thursday.</li>
<li>Biodexa Pharmaceuticals Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares fell 7.7% to $0.9964. Biodexa Pharmaceuticals shares jumped around 52% on Thursday after the company reported 12-month Phase 2 trial results for eRapa in treating Familial Adenomatous Polyposis.</li>
<li>Value Line, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALU#NASDAQ">VALU</a>) dipped 7.4% to $40.75.</li>
<li>Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) fell 6.8% to $56.07 after the company posted second-quarter results.</li>
<li>The Vita Coco Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCO#NASDAQ">COCO</a>) declined 6.3% to $28.49. Piper Sandler analyst Michael Lavery downgraded Vita Coco from Overweight to Neutral and lowered the price target from $29 to $28.</li>
<li>Bilibili Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) fell 5.5% to $16.65.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39748729/nvidia-to-rally-more-than-33-here-are-10-top-analyst-forecasts-for-friday">NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday</a></li>
</ul>

ACHR

AGRI

ASPI

BILI

CGBS

COCO

ERIC

EVGO

EYPT

FWRD

HOVR

IMMP

LCFY

LCID

LIPO

NISN

PEGY

Qualigen Therapeutics, Inc. - Common Stock

QLGN

RNLX

SANW

SISI

SNTG

SXTC

TOYO

VALU

VRPX

YGMZ

ZAPP

Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Verastem shares are trading higher after the company announced the first patient has been dosed in a Phase 1/2 trial in China, conducted by GenFleet Therapeutics, evaluating GFH375/VS-7375, a KRAS G12D inhibitor.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers for Wednesday morning as we check out all of the hottest news to start the day with!



Moving stocks this morning a partnerships, a public offering, clinical trial news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock is rocketing more than 123% alongside heavy pre-market trading.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) shares are soaring over 75% with strong early morning trading.</li>



<li>Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) stock is surging more than 45% <a href="https://www.nasdaq.com/press-release/hoth-therapeutics-partners-lts-therapy-systems-accelerate-novel-alzheimers-treatment">on a new partnership</a> to develop its Alzheimer&rsquo;s treatment.</li>



<li>Allarity Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) shares are increasing over 44% after encouraging investors to <a href="https://finance.yahoo.com/news/allarity-encourages-shareholders-vote-reverse-100000785.html">vote for a reverse stock split</a>.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) stock is heading more than 33% higher alongside strong pre-market trading.</li>



<li>Pieris Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/pirs-stock-quote/">PIRS</a>) shares are rising over 28% after <a href="https://www.nasdaq.com/press-release/palvella-therapeutics-and-pieris-pharmaceuticals-announce-definitive-merger-agreement">announcing a merger agreement</a>.</li>



<li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) stock is jumping more than 23% with heavy early morning trading today.</li>



<li>NewGenIvf (NASDAQ:<a href="https://investorplace.com/stock-quotes/nivf-stock-quote/">NIVF</a>) shares are climbing over 22% after providing a <a href="https://www.nasdaq.com/press-release/newgenivf-provides-update-potential-reverse-merger-covirix-2024-07-23">reverse merger update</a>.</li>



<li>Perfect Moment (NYSEMKT:<a href="https://investorplace.com/stock-quotes/pmnt-stock-quote/">PMNT</a>) stock is getting a close to 19% boost after announcing a <a href="https://www.nasdaq.com/press-release/perfect-moment-teams-quiet-platforms-establish-distribution-center-us-2024-07-22">distribution center agreement</a>.</li>



<li>Catheter Precision (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vtak-stock-quote/">VTAK</a>) shares are up more than 16% without any clear news this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Azitra&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/aztr-stock-quote/">AZTR</a>) stock is crashing over 73% but only <a href="https://investorplace.com/2024/07/why-is-azitra-aztr-stock-up-315-today/">after a massive rally yesterday</a>.</li>



<li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) shares are plummeting 28% on <a href="https://www.12newsnow.com/article/news/local/texas/conns-reportedly-planning-mass-closures/502-4db60564-6fdd-4ffa-ae26-899bec91f75c">reports of impending store closures</a>.</li>



<li>ATI Physical Therapy (NYSE:<a href="https://investorplace.com/stock-quotes/atip-stock-quote/">ATIP</a>) stock is diving more than 25% without any obvious news this morning.</li>



<li>Verastem (NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/">VSTM</a>) shares are tumbling over 25% on a <a href="https://finance.yahoo.com/news/verastem-oncology-announces-proposed-public-200500583.html">proposed public offering</a>.</li>



<li>Agape ATP (NASDAQ:<a href="https://investorplace.com/stock-quotes/atpc-stock-quote/">ATPC</a>) stock is taking an almost 24% beating after a rally yesterday.</li>



<li>AtlasClear (NYSEMKT:<a href="https://investorplace.com/stock-quotes/atch-stock-quote/">ATCH</a>) shares are sliding more than 22% despite a lack of news on Wednesday.</li>



<li>Sage Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/sage-stock-quote/">SAGE</a>) stock is dropping over 22% after reporting <a href="https://www.nasdaq.com/press-release/sage-therapeutics-and-biogen-announce-topline-results-phase-2-kinetic-2-study-sage">Phase 2 topline results</a>.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) shares are decreasing more than 21% <a href="https://www.nasdaq.com/press-release/volato-updates-fractional-program-additional-differentiated-benefits-2024-07-23">after a recent rally</a>.</li>



<li>Chijet Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/cjet-stock-quote/">CJET</a>) stock is slipping over 19% following yesterday&rsquo;s rally.</li>



<li>Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) shares close out our pre-market stock movers down more than 19% after a rally yesterday.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-24th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Verastem gets FDA orphan drug status for pancreatic cancer therapy

Verastem Non-GAAP EPS of -$0.61 beats by $0.45

In a report released yesterday, Justin Zelin from BTIG maintained a Buy rating on Verastem (VSTM – Research Report), with a price target of $13.00....

Buy Rating Justified by Verastem's Promising LGSOC Drug Prospects and Strong Market Position

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Verastem (NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/">VSTM</a>) just reported results for the second quarter of 2024.<ul><li>Verastem reported earnings per share of -61 cents. This was above the analyst estimate for EPS of -95 cents.</li><li>The company reported revenue of $10.00 million.</li><li>This was 19,900% better than the analyst estimate for revenue of $50,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/vstm-stock-earnings-verastem-for-q2-of-2024/">VSTM Stock Earnings: Verastem Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VSTM Stock Earnings: Verastem Beats EPS, Beats Revenue for Q2 2024

Analyst Sean Lee CFA from H.C. Wainwright maintained a Buy rating on Verastem (VSTM – Research Report) and decreased the price target to $7.00 from...

Buy Rating Affirmed for Verastem: Financial Stability and Promising Drug Pipeline Fuel Optimism

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on VSTM stock, giving a Buy rating on August 12. Graig Suvannavejh'...

Outperform Rating and $7 Target for Verastem Amidst LGSOC Treatment Potential and Stock Valuation Opportunity

Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity

Verastem ( ($VSTM) ) has shared an announcement. Verastem, Inc. unveiled promising data from their Phase 2 RAMP 201 trial at the IGCS 2024 meeting,...

Verastem Advances Cancer Treatment with Promising Trial Results

Analyst Srikripa Devarakonda from Truist Financial maintained a Buy rating on Verastem (VSTM – Research Report) and keeping the price target at $15...

Verastem Stock: Buy Rating Amid Market Overreaction and Promising Commercial Potential

HOTH

SLRX

VTAK

Legal

Press Releases

Bragar Eagel & Squire, P.C. Is Investigating Verastem, Helios, and LegalZoom and Encourages Investors to Contact the Firm

Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

Comments

Verastem

Noticias

Últimas noticias sobre Verastem (NASDAQ:VSTM) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL